Prospective, randomized pilot study of daily consensus interferon alfa (CIFN) and ribavirin for 52 weeks vs. extended duration to 72 weeks based on early virologic response for the initial treatment of difficult-to-treat patients with chronic hepatitis C genotype 1

Trial Profile

Prospective, randomized pilot study of daily consensus interferon alfa (CIFN) and ribavirin for 52 weeks vs. extended duration to 72 weeks based on early virologic response for the initial treatment of difficult-to-treat patients with chronic hepatitis C genotype 1

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs Interferon alfacon-1 (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Feb 2011 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 17 Feb 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 17 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top